NEW YORK, NY / ACCESSWIRE / October 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Edwards Lifesciences Corporation ("Edwards Lifesciences") (NYSE:EW) concerning possible violations of federal securities laws.
On October 28, 2022, Edwards announced 3Q 2022 financial results that missed revenue estimates and then lowered revenue guidance for the 4Q. Management blamed the poor sales performance on "U.S. hospital staffing shortages and COVID headwinds in Japan." Analysts commented that the slowdown seems "strangely sudden" and inconsistent "across the rest of MedTech."
Following this news, Edwards's stock price fell by $15.43 per share, or approximately 18% to close at $70.87 per share. To obtain additional information, go to:
https://zlk.com/pslra-1/edwards-lifesciences-lawsuit-submission-form?prid=106949&wire=1
or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212)363-7500.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212)363-7500
Fax: (212)363-7171
https://zlk.com/
SOURCE: Levi & Korsinsky, LLP
View the original
press release on accesswire.com
